Alpha Cognition Inc. Common Stock (ACOG)
Nasdaq · Healthcare · Biotechnology
$9.15+0.55%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $199M
- 52-week range
- $4.50 – $10.14
- 52-week change
- +22.97%
- EPS (trailing)
- −$1.32
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 12, 2026
Fiscal year to Dec 2025
- Revenue
- $10.2M
- Net income
- −$20.7M
- Operating margin
- −221.7%
- Diluted EPS
- −$1.18
- Free cash flow
- −$20.7M
From the company’s annual report on SEC EDGAR.
About Alpha Cognition Inc. Common Stock
Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.
Headquarters: Grapevine, United States · 71 employees · alphacognition.com